Cancer Informatics

Essential Technologies for Clinical Trials

Inbunden, Engelska, 2002

Av John S. Silva, Marion J. Ball, John S. Silva, Marion J. Ball, Christopher G. Chute, Judith V. Douglas, Curtis P. Langlotz, Joyce C. Niland, William L. Scherlis

1 459 kr

Beställningsvara. Skickas inom 7-10 vardagar

Fri frakt för medlemmar vid köp för minst 249 kr.

Cancer Informatics chronicles the development of the National Cancer Institute's new Cancer Informatics Infrastructure (CII) - an information management system infrastructure designed to faciliate clinical trials, provide for reliable, secure information exchange, and improve patient care. The book details the challenges involved in creating and managing such a knowledge base, including technologies, standards, and current, state-of-the-art applications.The ultimate goal of CII is to function as an enabler of clinical trials, expediting the clinical trials lifecycle, faciliating faster and safer drug development and more appropriate treatment choices for cancer patients. Contributors address the role the CII must play in converting the growing knowledge of genes, proteins, and pathways into appropriate preventative, diagnostic, and therapeutic measures. Presented in four sections, the first provides an overview of the processes involved in moving the infrastructure for cancer from theory into practice. Sections two through four offer the latest work done in the areas of technology, cancer-specific and national standards, and applications to faciliate clinical trials.

Produktinformation

Utgivningsdatum2002-01-08
Mått155 x 235 x undefined mm
FormatInbunden
SpråkEngelska
SerieHealth Informatics
Antal sidor377
FörlagSpringer-Verlag New York Inc.
MedarbetareKlausner,R.D.
ISBN9780387953281

Tillhör följande kategorier

Hälso- och sjukvård: administration och ledning inom Medicin
Onkologi inom Medicin

Section 1 The Vision.- Envisioning a National Cancer Information and Knowledge Environment.- 1 Translating Cancer Research into Cancer Care: Final Report of the Long Range Planning Committee.- 2 Visions of the Future.- 3 Clinical Trials in Practice.- Section 2 The Infrastructure.- Developing and Improving the Informatics Infrastructure to Support Clinical Research.- 4 Cancer Informatics: Lessons from the World of e-Business.- 5 Security and Privacy.- 6 Digital Libraries and Scholarly Communication.- Section 3 Standards and Vocabulary.- The Spectrum of Existing and Emerging Health Data Standards: Their Relevance and Application to Cancer Information.- 7 Cancer Data, Information Standards, and Convergent Efforts.- 8 Toward Terminology as Infrastructure.- 9 Clinical Terminologies for Data Analysis and Structured Data Entry.- 10 Information Standards Within the National Cancer Institute.- 11 CDE Development Model for Chest CT Screening for Lung Cancer.- 12 Pathology Standards in Cancer Informatics.- 13 Clinical Information Interchange with Health Level Seven.- 14 The Health Level Seven Reference Information Model.- 15 HIPAA Administrative Simplification Standards: Provisions of the Final Privacy Rule Related to Clinical Trials.- 16 Toward a Shared Representation of Clinical Trial Protocols: Application of the GLIF Guideline Modeling Framework.- 17 Informatics for Cancer Prevention and Control.- Section 4 Theory Into Practice.- Moving Toward the Vision: Putting Applications in Place.- 18 Selection of Oncology Information Systems.- 19 Clinical State Diagrams and Informatics Tools for Clinical Trial Protocols.- 20 Support for the Cancer Patient: An Internet Model.- 21 Increasing Clinical Trial Awareness and Accrual Via the Web.- 22 ClinicalTrials.gov: Linking Patients to Medical Research.- 23 The National Cancer Institute’s net-Trials™.- 24 iN: A Community-Based Cancer Informatics and Clinical Trials Network.- 25 Consumer Health Informatics.- 26 An Internet-Based Data System for Outcomes Research.

From the reviews:"People running cancer trials should read this book. It is about the US National Cancer Institute’s plans to ‘liberate cancer trials from paper’. … The chapters were written by leading US experts. The content is detailed, technical, and surprisingly well-written. They give a clear vision of how cancer trials are likely to develop over the next 20 years. This book is informative, interesting, and … enjoyable." (M Stockler, Cancer Forum, Vol. 27 (3), 2003)